CSL (ASX:CSL; USOTC:CSLLY), a global biotechnology company, announced on Sunday the top-line outcome from its Phase three AEGIS-II trial assessing the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in decreasing the risk of major adverse cardiovascular events (MACE) in subjects subsequent to an acute myocardial infarction (AMI).
The study has not met its primary efficacy endpoint of MACE decrease at 90 days. Due to this, there are no plans for a near-term regulatory filing. The study did not identify any major safety or tolerability concerns with the product. Further evaluation of AEGIS-II is ongoing and primary outcome will be showcased at the American College of Cardiology Scientific Sessions, scheduled at 6 April 2024, and published in a peer-reviewed journal.
The AEGIS-II trial enrolled more than 18,200 subjects from more than 850 sites in 49 countries. Subjects were randomised to receive four weekly doses of the product or placebo started within five days of first medical contact.
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration